Online inquiry

IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ524MR)

This product GTTS-WQ524MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Psoriasis, Organ transplant immunological rejection suppression research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ524MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9925MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ6872MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ11660MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ8377MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ3447MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ788MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ12327MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ4343MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW